
CAS 1103522-45-7
:Aprocitentan
- Act-132577
- Prezzo più basso
- Prezzo più alto
- Purezza più bassa
- Purezza più alta
- Consegna più veloce
Ref: IN-DA008TD9
1mg99,00€5mg196,00€10mg201,00€25mg239,00€50mg535,00€100mg556,00€250mg830,00€1g2.293,00€Despropyl Macitentan
CAS:Compounds containing a pyrimidine ring, whether or not hydrogenated, or piperazine ring in the structureFormula:C16H14Br2N6O4SColore e forma:Off-White SolidPeso molecolare:543.9164N-Despropyl Macitentan (Aprocitentan)
CAS:Formula:C16H14Br2N6O4SColore e forma:White To Off-White SolidPeso molecolare:546.19Ref: 4Z-M-128003
5mgPrezzo su richiesta100mgPrezzo su richiesta10mg1.191,00€25mg2.144,00€50mg3.334,00€Aprocitentan
CAS:Aprocitentan (ACT-132577) is ETA and ETB antagonist .Formula:C16H14Br2N6O4SPurezza:97.35%Colore e forma:White SolidPeso molecolare:546.19N-(5-(4-Bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)sulfamide
CAS:N-(5-(4-Bromophenyl)-6-(2-((5-bromopyrimidin-2-yl)oxy)ethoxy)pyrimidin-4-yl)sulfamideFormula:C16H14Br2N6O4SPurezza:99%Peso molecolare:546.19N-Despropyl-macitentan
CAS:Prodotto controllatoApplications N-Despropyl-macitentan, is an active metabolite which is part of a family of endothelin receptor antagonist that allows for treatment of pulmonary arterial hypertension (PAH)
References Atsmon, J., et al.: Clin. Pharmacokinet., 525, 685 (2013); Sidharta, P.N., et al.: Clin. Drug Invest. (2014)Formula:C16H14Br2N6O4SColore e forma:NeatPeso molecolare:546.19Aprocitentan
CAS:Apcitentan is a vasoactive drug that belongs to the group of endothelin receptor antagonists. It is used in the treatment of erectile dysfunction and pulmonary hypertension. Apcitentan inhibits the angiotensin system, which includes angiotensin-converting enzyme (ACE), angiotensin II type 1 receptor (AT1R) and angiotensin II type 2 receptor (AT2R). This inhibition increases the levels of endothelin and dopamine β-hydroxylase, thereby decreasing blood pressure. Apcitentan has been shown to increase glomerular filtration rate and reduce proteinuria in patients with chronic kidney disease. In vivo studies have shown that apcitentan is rapidly absorbed from the gastrointestinal tract, reaching peak concentrations within one hour. The pharmacodynamics of apcitentan are characterized by an inhibitory effect on pde5. Pharmacokinetic studies have found that apcitentan is metabolized by CYP
Formula:C16H14Br2N6O4SPurezza:Min. 95%Peso molecolare:546.19 g/molRef: ST-EA-CP-M5016
10mgPrezzo su richiesta25mgPrezzo su richiesta50mgPrezzo su richiesta100mgPrezzo su richiesta










